Cargando…
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
PURPOSE: Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison h...
Autores principales: | Millul, Jacopo, Koepke, Lennart, Haridas, Gaonkar Raghuvir, Sparrer, Konstantin M. J., Mansi, Rosalba, Fani, Melpomeni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382406/ https://www.ncbi.nlm.nih.gov/pubmed/37261473 http://dx.doi.org/10.1007/s00259-023-06272-7 |
Ejemplares similares
-
Development
of a New Class of CXCR4-Targeting Radioligands
Based on the Endogenous Antagonist EPI-X4 for Oncological Applications
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2023) -
SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2021) -
Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021) -
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023) -
Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)